ANN ARBOR, Mich.- – (BUSINESS WIRE)- – Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-organize biopharmaceutical organization fundamentally centered around creating novel medications for vagrant endocrine infections with critical neglected needs, today reported that Geoff Nichol, M.B., Ch.B., M.B.A., has been selected to the Board of Directors. Dr. Nichol presently fills in as Chief Medical Officer at BioMarin where he supervises a functioning arrangement of clinical improvement programs and has driven various projects through late-organize clinical examinations and administrative endorsement.
“We respect the profound ability and bits of knowledge from Dr. Nichol,” said Julia C. Owens, Ph.D., President and Chief Executive Officer at Millendo Therapeutics. “His experience over the full range of medication advancement, especially in uncommon maladies and late-arrange clinical improvement, just as his solid information on the administrative endorsement process supplements our present board. His point of view will have a critical effect as we plan our progress to a business arrange association.” “Millendo has assembled a strong establishment with its lead up-and-comer lipopeptide, and the clinical information to date are promising,” said Dr. Nichol. “I am eager to help manage the organization on their procedure to progress livoletide and other pipeline resources and I anticipate working intimately with this devoted, tolerant centered group to additionally create potential therapeutics for those living with uncommon endocrine ailments.”
Dr. Nichol brings to the Millendo Board of Directors almost 30 years of involvement with sedate advancement, including his viewpoints as CMO at BioMarin. Before joining the authority group at BioMarin, Dr. Nichol drove the pre-clinical improvement of a few IND up-and-comers as the EVP of R&D at Sangamo. He recently held senior situations at Medarex Inc. (gained by Bristol Myers Squibb), Novartis and SmithKline Beecham. Dr. Nichol got a B.Med.Sc., M.B., Ch.B., or what might be compared to an M.D. in the U.S., from Otago University Medical School in New Zealand and an M.B.A. from Warwick University in the United Kingdom.